AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Change in Working Capital · Q4 FY2024 · quarter ended Dec 2024
Change in working capital of -€1.62M in Q4 FY2024
Q4 FY2024 change in working capital was -€1.62M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
Currency unavailable · from the cash flow
No Change in Working Capital data reported for this period type.
Change in Working Capital vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $90.89M USD | +54.3% | — | 39.1% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $13.49M USD | -58.1% | — | 182.4% |
| LTM Mar 2026 | $2.98M USD | -83.4% | — | 35.6% | |
| LTM Mar 2026 | $2.16M USD | -139.0% | — | — | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -70.8% | — | 39.1% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.